On April 24, 2026, the Zhuhai-Hong Kong-Macao Biomedical Industry Innovation & Development Conference, themed Pooling Greater Bay Area Biomedical Mindsets, Galvanizing Jinwan’s Innovative Growth, grandly opened in Jinwan District, Zhuhai. The event gathered nearly 200 industry representatives, including members of the Chinese Academy of Sciences and Chinese Academy of Engineering, competent authorities from Zhuhai, Hong Kong and Macao, research institutes affiliated with Hong Kong and Macao universities, leading pharmaceutical enterprises, tertiary public hospitals and industrial investment institutions.

Three landmark outcomes were unveiled at the conference: the 30-Minute Cross-Border Biomedical Research Translation Corridor covering Macao, Hengqin and Jinwan, the first batch list of 49 cross-border (Macao) biomedical translation projects, and the 2026 first batch list of 10 biomedical application scenario demands released by Jinwan District. A centralized signing ceremony for Jinwan’s key newly introduced biomedical projects of 2026 was held during the session.

As a benchmark Cell and Gene Therapy (CGT) project in the Greater Bay Area, the Zhuhai Industrialization Base Project of Beijing Qichengsheng Bio completed official signing and site entry on-site, making the company a flagship CGT enterprise prioritized for introduction at this conference.

The batch of signed projects focuses on cutting-edge tracks including cell and gene therapy, mRNA innovative drugs and high-end medical devices, representing a core initiative for Jinwan District to build a closed-loop cross-border biomedical industrial ecosystem featuring Macao R&D, Hengqin Translation, Jinwan Manufacturing.

Supported by a full-chain support system launched at the conference—including tailored cross-border translation policies, a dedicated CGT Innovation Center, open clinical scenarios in public hospitals and special industrial funds—the Qichengsheng project will settle in Zhuhai International Health Port. The company will fully deploy GMP-grade industrialization bases for mRNA nucleic acid modification, lipid nanoparticle (LNP) delivery and autologous DC tumor vaccines, establishing a complete industrial pipeline covering basic scientific research in Hong Kong and Macao, multi-center clinical trials across the Greater Bay Area, and large-scale commercial manufacturing.